Chlortetracycline

CHEMBL404520 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
478.9 g/mol
LogP
-1.3
Phase
4

The first tetracycline antibiotic discovered, originally derived from the soil bacterium Streptomyces aureofaciens, inhibiting bacterial protein synthesis by blocking aminoacyl-tRNA binding to the ribosome. It was historically used to treat a wide range of bacterial infections but has been largely superseded in human medicine. It continues to see use in veterinary medicine and agriculture.

Moleküler Ağırlık

478,9000 g/mol

LogP

-1,30

TPSA

182,00 Ų

Lipinski RO5

Geçer

Etki Mekanizması

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12

InChI

InChI=1S/C22H23ClN2O8/c1-21(32)7-6-8-15(25(2)3)17(28)13(20(24)31)19(30)22(8,33)18(29)11(7)16(27)12-10(26)5-4-9(23)14(12)21/h4-5,7-8,15,26,28-29,32-33H,6H2,1-3H3,(H2,24,31)/t7-,8-,15-,21-,22-/m0/s1

Molecular Formula

C22H23ClN2O8

HBD / HBA

6 / 9

Döndürülebilir Bağlar

2

Ağır Atomlar

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

The first tetracycline antibiotic discovered, originally derived from the soil bacterium Streptomyces aureofaciens, inhibiting bacterial protein synthesis by blocking aminoacyl-tRNA binding to the ribosome. It was historically used to treat a wide range of bacterial infections but has been largely superseded in human medicine. It continues to see use in veterinary medicine and agriculture.

Binds reversibly to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the ribosomal acceptor (A) site. This inhibits bacterial protein synthesis in a bacteriostatic manner.

Yes, Chlortetracycline is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL404520. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 54675777. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.